

**OPACH Presentation:** Andrea LaCroix, [alacroix@health.ucsd.edu](mailto:alacroix@health.ucsd.edu)

From Ulrike Peters : Will you have a sleep component in OPACH II as you have the technique

**WHISH Presentation:** Marcia Stefanick, [stefanick@stanford.edu](mailto:stefanick@stanford.edu)

From Ulrike Peters : Congratulations for conducting this large pragmatic trial!

WHISH is focused on CVD have you looked at other outcomes, like mild cognitive impairment, cancer or diabetes

**Poster Presentations:**

**Bernhard Haring:** [haring.bernhard@gmail.com](mailto:haring.bernhard@gmail.com)

From Mike LaMonte : Perhaps DBPV reflects more of an atherosclerotic consequence than does SBPV, and thus more relevant to ischemic CVD outcomes, such as HFref

From JoAnn Manson : Differences in results according to use, or non-use, of antihypertensive medications? Stratified analyses?

From ileng : Does BPV distinguish BP oscillation and monotonic change over time?

**Purva Jain:** [jpurva89@gmail.com](mailto:jpurva89@gmail.com)

From Lisa : Have you looked at reverse causation?

**Benjamin Schumacher:** [benschumacher12@gmail.com](mailto:benschumacher12@gmail.com)

From Lisa : Again, is there evidence of a reverse causation? Those who worry about falls may walk less...

**Sylvia Smoller:** [sylvia.smoller@einsteinmed.org](mailto:sylvia.smoller@einsteinmed.org)

From JoAnn Manson : Was pulse pressure a predictor of risk?

From Lisa Martin : very important information!

From Lisa : Great talks and posters--thank you presenters!